Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the low-grade glioma market grown in recent years?

In recent times, the market size of low-grade glioma has experienced substantial growth. It’s projected to increase from its size of $1.39 billion in 2024 to $1.48 billion in 2025, displaying a compound annual growth rate (CAGR) of 6.1%. This evolutionary growth during the historic period can be credited to factors such as heightened awareness about brain tumors, a rise in oncology research funding, a surge in the designation of orphan drugs, the broadening of telemedicine, and improved access to healthcare.

How is the low-grade glioma market size expected to evolve during the forecast period?

The market size of low-grade glioma is predicted to exhibit substantial growth in the forthcoming years, reaching a valuation of $1.86 billion in 2029 with a compound annual growth rate (CAGR) of 5.9%. The surge during the forecast period is primarily due to factors such as an increase in the elderly population, surge in healthcare spending, escalating cases of brain tumors, growth in government-led initiatives, and a rise in the occurrence and prevalence of high-grade gliomas. Key trends during the forecast period consist of improvements in imaging technologies, advancements in radiation therapies, the advent of chemotherapy regimens, the expansion of clinical trials, and the integration of immunotherapy.

Get your low-grade glioma market report here!

https://www.thebusinessresearchcompany.com/report/low-grade-glioma-global-market-report

Which key drivers are propelling the low-grade glioma market’s growth?

The upsurge in occurrences of brain tumors is anticipated to boost the development of the low-grade glioma market in the future. Brain tumors are abnormal cell growths that can appear in the brain or nearby regions and can be benign or malignant. Factors such as increased radiation exposure, environmental pollutants, genetic susceptibilities, and aging contribute to the increasing brain tumor incidence. Low-grade gliomas effectively manage brain tumors by using state-of-the-art diagnostic methods and target-based treatments such as surgery, radiation, and chemotherapy, thus slowing tumor growth, maintaining neurological functions, and enhancing patient results. It is therefore essential to detect promptly and customize treatments for other brain tumors mirroring similar growth trends. The Central Brain Tumor Registry of the United States (CBTRUS), a non-profit organization based in the US, stated in October 2023 that in 2022, the global incidence rate of primary malignant brain tumors was roughly 3.5 per 100,000. Rates were high in high-income countries (4.9 per 100,000) compared to low-middle (2.4 per 100,000) and low-income countries. The escalating incidence of brain tumors, consequently, is propelling the advancement of the low-grade glioma market.

What are the market segments in the low-grade glioma industry?

The low-grade glioma market covered in this report is segmented –

1) By Drug Type: Trametinib, Dabrafenib, Ivosidenib, Mirdametinib

2) By Treatment: Surgery, Chemotherapy, Radiation

3) By Route Of Administration: Topical, Oral

4) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21215&type=smp

Which leading companies are shaping the growth of the low-grade glioma market?

Major companies operating in the low-grade glioma market are McKesson Corporation, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Daiichi Sankyo Company Limited, Ipsen S.A., BeiGene Ltd., NovoCure Limited, Les Laboratoires Servier, Day One Biopharmaceuticals Inc., CStone Pharmaceuticals Co. Ltd., AnHeart Therapeutics Inc., Apollomics Inc., Agios Pharmaceuticals Inc., BioMed Valley Discoveries Inc., Avistone Biotechnology Co. Ltd., NextSource Biotechnology LLC, Sunesis Pharmaceuticals Inc.

How are evolving market trends shaping low-grade glioma Strategies?

Key businesses in the low-grade glioma market are concentrating their efforts on incorporating combination therapies and targeted treatments, such as genetic modification drugs, in order to maintain a competitive advantage and improve the care for children suffering from low-grade glioma. Genetic modification drugs are a type of targeted treatment that aim to change or inhibit specific gene mutations or irregularities within cells. These drugs aim to treat illnesses like cancer by interfering with the processes that instigate unchecked cell growth. For example, Day One Biopharmaceuticals, a biotech company based in the US, launched Tovorafenib (Ojemda) in May 2024, following fast-tracked FDA approval. This targeted therapy is created for children aged six months or older with inoperable or recurrent low-grade glioma (LGG) with BRAF gene alterations. The once-weekly oral treatment offers convenience and addresses an important need for pediatric LGG patients who had previously limited treatment choices.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21215

Which geographic areas are influencing the growth of the low-grade glioma market?

North America was the largest region in the low-grade glioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the low-grade glioma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Infertility Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/infertility-treatment-global-market-report

Fertility Treatments Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/fertility-treatments-global-market-report

Urinary Tract Infection Treatment Global Market Report 2025

https://thebusinessresearchcompany.com/report/urinary-tract-infection-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: